Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of AS03-adjuvanted H1N1 pandemic influenza vaccine co-administered with Fluarix in adults aged 61 years and older
2009-013931-39Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Fluarix and pandemic influenza vaccine (h1n1) (split virion, inactivated, adjuvanted) in influenza A virus infection (H1N1) and seasonal influenza (2 arms), sponsored by GSK. Primary endpoint: Humoral immune response to vaccine-homologous H1N1 virus after second H1N1 dose. Started Sep 2009; status: completed.
02
Drugs
Fluarixpandemic influenza vaccine (h1n1) (split virion, inactivated, adjuvanted)
03
Conditions
influenza A virus infection (H1N1)seasonal influenza
Beyond the preview
Go deeper on 2009-013931-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013931-39.